Peginterferon alfa-2a
(Redirected from Roferon A)
Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, a type of interferon used as an antiviral and antineoplastic agent. It is primarily used in the treatment of hepatitis C and hepatitis B infections. Peginterferon alfa-2a is marketed under the brand name Pegasys.
Mechanism of Action[edit | edit source]
Peginterferon alfa-2a works by binding to specific receptors on the surface of cells, initiating a complex cascade of intracellular events. This leads to the activation of multiple genes that inhibit viral replication and modulate the immune response. The pegylation process, which involves attaching a polyethylene glycol (PEG) molecule to the interferon, increases the half-life of the drug, allowing for less frequent dosing compared to non-pegylated interferons.
Indications[edit | edit source]
Peginterferon alfa-2a is indicated for the treatment of:
- Chronic hepatitis C (CHC) in patients with compensated liver disease.
- Chronic hepatitis B (CHB) in patients with compensated liver disease and evidence of viral replication and liver inflammation.
Administration and Dosage[edit | edit source]
Peginterferon alfa-2a is administered via subcutaneous injection. The dosage and duration of treatment vary depending on the condition being treated and the patient's response to therapy. For chronic hepatitis C, it is often used in combination with ribavirin.
Side Effects[edit | edit source]
Common side effects of peginterferon alfa-2a include:
- Flu-like symptoms (fever, chills, muscle aches)
- Fatigue
- Depression
- Insomnia
- Anorexia
- Nausea
- Injection site reactions
Serious side effects can include:
Contraindications[edit | edit source]
Peginterferon alfa-2a is contraindicated in patients with:
- Hypersensitivity to interferon alfa or any component of the formulation
- Autoimmune hepatitis
- Decompensated liver disease
Related Pages[edit | edit source]
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
